1-3 of 3
Charles Craddock, FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, DipRCPath, Simon Hallam, MRCP, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2007) 110 (11): 2713.
https://doi.org/10.1182/blood.V110.11.2713.2713
Published: 2007
Journal Articles

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, BSc, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath
Journal: Blood
Blood (2006) 108 (11): 3542.
https://doi.org/10.1182/blood.V108.11.3542.3542
Published: 2006
Journal Articles

A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Heather E. Oakervee, MRCPath, Nicola Foot, BSc, Samir Agrawal, PhD, Patricia Smith, RGN, Charles Craddock, FRCPath, Catherine Williams, FRCPath, Supratik Basu, FRCPath, Jamie D. Cavenagh, MD
Journal: Blood
Blood (2005) 106 (11): 2555.
https://doi.org/10.1182/blood.V106.11.2555.2555
Published: 2005